Compounded GLP-1 vs FDA-Approved Weight Loss Medications: What Patients Need to Know

Recent discussion in the medical community has focused on compounded GLP-1 medications after Eli Lilly issued a public letter on March 12 warning about potential impurities found in compounded tirzepatide products mixed with vitamin B12.

According to Lilly, laboratory testing identified a previously unreported impurity that may form when tirzepatide is combined with B12. Lilly reported the findings to the FDA and urged patients and providers to exercise caution with compounded tirzepatide products containing additives.

At the same time, compounding organizations have requested additional transparency regarding the testing methods and data used to reach that conclusion.

Both points can be true.

Pharmaceutical companies have financial interests in protecting their products, but potential impurities in injectable medications are also not something that should be casually dismissed.

For patients trying to navigate the rapidly growing market of weight loss medications, the conversation raises an important question: what is the difference between FDA-approved medications and compounded drugs?

What Are GLP-1 Medications?

GLP-1 receptor agonists are medications that help manage type 2 diabetes and obesity. FDA-approved versions include semaglutide (Ozempic, Wegovy, Rybelsus) and tirzepatide (Mounjaro, Zepbound). These medications have undergone extensive testing to prove they are safe and effective.

What Does "Compounded" Mean?

Compounded medications are custom-made by pharmacies, typically for patients who need a specific dose or formulation not available commercially. Compounding has a legitimate and important role in medicine, for example, creating a liquid version of a medication for a child who cannot swallow pills, or preparing a topical cream with a concentration not commercially available.

The key phrase is "not available commercially." Under federal law, compounded drugs are only allowed to differ from commercially available medications if the prescriber determines the change produces a significant difference for a specific patient. This determination must be clinically justified and documented.

Compounding was never intended to mass-produce copies of commercially available, FDA-approved medications. But that is exactly what happened during the GLP-1 shortage.

What Is a 503A Compounding Pharmacy?

A 503A pharmacy is a traditional compounding pharmacy operating under Section 503A of the Federal Food, Drug, and Cosmetic Act. These pharmacies prepare medications for individual patients based on a valid prescription from a licensed prescriber.

• Medication is prepared for a specific patient based on an individual prescription
• Oversight is primarily through state boards of pharmacy, not the FDA
• Must follow USP §797 standards for sterile compounding (procedures for preparing sterile medications to prevent microbial contamination)
• Must comply with USP §800 for hazardous drug handling when applicable
• Products are not FDA-approved medications
• Compounded drugs do not undergo FDA pre-market safety or efficacy review
• Are not required to report adverse events to the FDA
• Cannot mass-produce or distribute medications across state lines without restrictions

Compounding can be medically appropriate in situations such as patients requiring custom doses, allergies to inactive ingredients in commercial products, or alternative dosage forms. However, the oversight for 503A pharmacies varies significantly from state to state. Some states have rigorous inspection programs. Others do not.

It is important to understand what USP §797 and USP §800 actually cover. USP §797 sets standards for sterile compounding — the procedures, environment, and testing meant to prevent microbial contamination. USP §800 addresses safe handling of hazardous drugs. These are meaningful quality standards, but they are focused on sterility and safe handling. They are not designed to detect chemical impurities, degradation products, or reaction byproducts that may form when ingredients are combined.

What Is a 503B Outsourcing Facility?

A 503B outsourcing facility is a larger compounding facility that can produce medications in bulk. These facilities were created by the Drug Quality and Security Act of 2013, largely in response to the 2012 New England Compounding Center (NECC) fungal meningitis outbreak that killed 64 people and infected 753 across 20 states (CDC).

• Must register with the FDA and are subject to FDA inspections
• Must follow Current Good Manufacturing Practices (cGMP), which can include analytical testing depending on the product and internal quality program
• Can compound medications in larger batches without individual patient prescriptions
• Are required to report adverse events to the FDA
• Must label products with ingredient lists and beyond-use dating
• Can distribute medications across state lines

503B facilities have more oversight than 503A pharmacies, but there is a critical distinction that patients often miss: products made by 503B facilities are still not FDA-approved medications.

While a well-run 503B facility operating under cGMP could potentially detect chemical impurities through analytical testing, it is not guaranteed or standardized the way it is in an FDA drug approval process. 503B facilities do not have to demonstrate the same level of impurity characterization, forced degradation studies, or stability data required for FDA drug approval. 503A and 503B describe compounding pathways, not FDA drug approval.

Key Differences Between Compounded and FDA-Approved GLP-1 Medications

FDA-approved medications have been rigorously tested in clinical trials involving thousands of patients. The FDA reviews data on safety, effectiveness, proper dosing, and manufacturing quality before approval. Every batch is made under strict quality control standards.

Compounded medications do not undergo FDA premarket review for safety, effectiveness, or quality. They are not tested in clinical trials, and there are no standardized formulas (called USP monographs) available for semaglutide or tirzepatide. The FDA approval process typically takes 10 to 15 years and costs hundreds of millions of dollars. It exists for one reason: to protect patients.

The raw ingredient may be similar. The final product is not the same.

Why Additives Like B12 Are Being Discussed

Some compounded GLP-1 formulations include additives such as vitamin B12, glycine, niacinamide, and L-carnitine. These additions are often marketed as "personalized formulations."

However, under federal law, compounded drugs are only allowed to differ from commercially available medications if the prescriber determines the change produces a significant difference for a specific patient. The addition of vitamins does not automatically make a compounded drug safer, more effective, or compliant with regulatory standards. It also does not convert the product into a dietary supplement.

Injectable GLP-1 medications remain prescription drugs, regardless of added ingredients. To date, there is limited evidence that these additive combinations have been studied for safety or demonstrated clinical benefit when combined with tirzepatide or semaglutide.

What the Eli Lilly Warning Means

On March 12, 2026, Eli Lilly published an open letter to patients and healthcare providers about findings from their testing of compounded tirzepatide products mixed with vitamin B12.

Lilly's testing revealed significant levels of an unknown impurity created by a chemical reaction between tirzepatide and vitamin B12. The safety profile of this impurity has never been studied. No one knows whether this impurity is toxic, whether it triggers immune reactions, how it is absorbed or metabolized in the body, whether it interferes with GLP-1 or GIP receptor activity, or whether it accumulates in tissues over time.

At the moment, Lilly's warning represents a potential safety signal, not a final scientific conclusion. More independent data will be necessary to fully evaluate the claim. However, potential chemical instability or impurities in injectable medications should always be evaluated carefully. The goal of medicine should never be to dismiss safety concerns prematurely. It should be to investigate them thoroughly.

Why Standard Compounding Tests Would Not Catch This

One question patients may ask is: don't compounding pharmacies test their products?

They do, but the testing they perform is designed to catch different problems. Standard sterility testing (such as USP §71 sterility testing or USP §85 endotoxin testing) is designed to detect microbial contamination, bacterial growth, and fungal contamination. These are important quality checks, but they do not detect chemical degradation products or reaction impurities.

If tirzepatide chemically reacts with B12 to form a new compound, sterility testing would not identify it. Detecting chemical impurities requires entirely different analytical methods: techniques like high-performance liquid chromatography (HPLC), mass spectrometry, impurity profiling, and forced degradation studies. These are part of the pharmaceutical chemistry validation (known as CMC: Chemistry, Manufacturing, and Controls) that manufacturers must complete during the FDA drug approval process.

For FDA-approved drugs, the manufacturer must demonstrate degradation pathways, identify and set limits for impurities, and prove stability under different conditions and compatibility with all excipients. This is a major part of why the FDA approval process takes years and costs hundreds of millions of dollars.

A well-run 503B facility could theoretically perform this level of analytical testing, but it is not required and not standardized the way it is for FDA-approved drugs. For 503A pharmacies following USP §797, this type of chemical impurity testing is generally outside the scope of their quality programs entirely.

From a scientific standpoint, Lilly's claim is plausible. Peptides like tirzepatide are chemically sensitive molecules. Adding other compounds could theoretically cause oxidation, deamidation, peptide cleavage, or adduct formation. Vitamin B12 is a large cobalt-containing molecule that can participate in redox reactions under certain conditions. Whether it actually occurs at clinically significant levels still requires independent verification, but it is not the kind of concern that should be dismissed without investigation.

Safety Concerns With Compounded GLP-1 Products

Recent studies and FDA reports have identified several safety issues with compounded GLP-1 medications beyond the Lilly findings:

• Dosing errors: The FDA reported cases where patients received 5 to 20 times the intended dose due to confusion about units of measurement, varying concentrations, and unclear labeling. Some patients required hospitalization for severe nausea, vomiting, dehydration, pancreatitis, and gallstones (FDA Safety Communication, July 2024).
• Product quality issues: Analysis of compounded products found problems with purity, contamination, and inconsistent concentrations. Some products contained different chemical forms of the active ingredient that have not been proven safe or effective.
• Bacterial contamination and high endotoxin levels in finished products
• At least one product that, according to Lilly's testing, was identified as nothing more than sugar alcohol
• Black particulate matter found in vials
• Non-sterile manufacturing conditions documented by FDA inspections
• Over 520 adverse event reports for compounded semaglutide and 480 for compounded tirzepatide submitted to the FDA as of April 2025, primarily through the MedWatch program by patients, healthcare providers, and 503B facilities. Because 503A pharmacies are not required to report adverse events, the actual number is likely significantly higher.

These are not isolated incidents. They represent systemic quality control failures inherent to a manufacturing process that was never designed to produce injectable medications at scale.

The Financial Reality: Understanding the Incentives

It is worth understanding the financial dynamics at play in this discussion.

Compounded GLP-1 medications can be a significant revenue source for telehealth companies and weight loss clinics. A clinic can purchase compounded semaglutide or tirzepatide at a low wholesale cost from a compounding pharmacy, then dispense or resell it to patients at a markup. The clinic controls the supply chain and captures the margin.

By contrast, when a clinic prescribes FDA-approved medications like Zepbound or Wegovy, the patient fills the prescription at a pharmacy. The prescribing clinic typically earns nothing from the medication itself. Programs like Eli Lilly Direct (LillyDirect) offer Zepbound directly to patients at reduced prices, but the prescribing clinic generally receives no financial benefit from the medication sale.

This creates a dynamic where the financial incentive for clinics may favor compounded products over FDA-approved alternatives. Patients benefit from understanding these economics when evaluating recommendations from any provider.

The Legal Landscape Has Changed

The regulatory environment for compounded GLP-1 medications shifted significantly in 2024 and 2025.

The FDA declared the tirzepatide shortage resolved in October 2024, and after a legal challenge from the Outsourcing Facilities Association (OFA), issued a Declaratory Order on December 19, 2024 confirming the resolution. The enforcement discretion period ended for 503A pharmacies on February 18, 2025 and for 503B outsourcing facilities on March 19, 2025. On May 7, 2025, the U.S. District Court for the Northern District of Texas upheld the FDA's determination and denied the OFA's preliminary injunction (FDA Declaratory Order, December 2024; U.S. District Court, N.D. Texas, May 2025).

The FDA declared the semaglutide shortage resolved on February 21, 2025. The enforcement discretion period ended for 503A pharmacies on April 22, 2025 (60 days) and for 503B outsourcing facilities on May 22, 2025 (90 days) (FDA Drug Shortage Database, February 2025).

After these dates, compounding pharmacies can no longer rely on the drug shortage exception to compound "essentially a copy" of FDA-approved semaglutide or tirzepatide products. Patients who are still obtaining compounded GLP-1 medications should understand that the regulatory environment has changed, and the products they are using may no longer be legally produced under the shortage exception.

FDA-Approved Medications Are Now More Accessible Than Ever

One of the arguments historically used to justify compounded medications was cost. FDA-approved GLP-1 medications were expensive, and compounded versions were cheaper.

That pricing gap has narrowed dramatically in 2026:

• Zepbound (tirzepatide) 2.5mg starting dose: $299/month through LillyDirect
• Zepbound 5mg dose: $399/month through LillyDirect
• Zepbound higher doses (7.5-15mg): $449/month through LillyDirect Self Pay Journey Program
• Patients with commercial insurance and a savings card: as low as $25/month

These prices are competitive with many compounded products, and they come with the assurance of FDA-approved manufacturing, verified ingredients, standardized dosing in pre-filled pens, and full adverse event monitoring.

Questions to Ask Your Healthcare Provider

Whether you are considering GLP-1 medications for the first time or currently using a compounded version, here are important questions to discuss with your provider:

• Is there an FDA-approved medication that meets my needs?
• If a compounded medication is recommended, why is it necessary instead of an FDA-approved option?
• Is the compounding pharmacy registered with the FDA (503B) or licensed by the state (503A)?
• What quality testing has been done on this specific compounded product?
• What are the specific risks of the compounded version compared to FDA-approved medications?

What You Should Do If You Are Currently Using Compounded GLP-1 Medications

If you are currently using a compounded GLP-1 medication, do not stop abruptly without consulting a physician. Instead:

• Contact your healthcare provider to discuss transitioning to an FDA-approved alternative
• Ask specifically whether your compounded product contains any additives (B12, glycine, carnitine, etc.) and understand that these combinations have never been tested for safety
• Report any adverse effects to the FDA MedWatch program and to Lilly's Answers Center at 1-800-LillyRx (1-800-545-5979) if using a tirzepatide product
• Explore manufacturer programs like LillyDirect for affordable access to FDA-approved tirzepatide

Our Commitment to Patient Safety

At Thrive RX, patient safety is the foundation of everything we do.

We prescribe only FDA-approved medications because we believe they provide the most reliable safety, manufacturing, and quality standards available today. Every patient undergoes a thorough physician assessment before starting treatment to ensure medications are appropriate and safe. Even with FDA-approved medications, we monitor patients closely with follow-up visits and laboratory testing.

But medications are only one part of the solution. Our programs emphasize whole food nutrition, sustainable eating habits, physical activity, and metabolic health. Our goal is not long-term medication dependence. It is helping patients retrain hunger signals, build healthy habits, and achieve sustainable weight loss.

The Bottom Line

Compounding pharmacies play an important role in medicine when patients have unique needs. But the regulatory pathways for compounding are not the same as FDA approval, and patients deserve to understand those differences.

The current discussion surrounding compounded GLP-1 medications highlights a broader principle: patient safety should always come first. Transparency, evidence, and responsible medical care should guide decisions, not marketing claims or shortcuts.

If you experience any side effects from a weight loss medication, report them to the FDA through MedWatch at fda.gov/medwatch.

Available in Florida

The compounded vs FDA-approved decision matters in every state. Thrive RX is a 100% telehealth practice serving patients in Florida, including Miami, Weston, Fort Lauderdale, Orlando, Tampa, Jacksonville, and every city in between. We prescribe FDA-approved GLP-1 medications only, never compounded, to every patient we serve.